PROGRAM CHAIR
Mary Beth Scholand, MD
Professor, Internal Medicine
University of Utah
Salt Lake City, Utah
PROGRAM OVERVIEW
This engaging online enduring educational snapshot program provides clinicians with a review of idiopathic pulmonary fibrosis (IPF) pathophysiology and evidence-based diagnostic criteria essential for accurate, timely diagnosis of this complex disease of exclusion. Expert faculty will critically examine current treatment approaches, new FDA approvals, and emerging investigational targeted therapies poised to reshape the IPF treatment landscape. The program will also include a short whiteboard animation illustrating the distinct mechanisms of approved and investigational therapies, supporting deeper understanding of how new agents are redefining therapeutic approaches in IPF.
TARGET AUDIENCE
This educational enduring activity is designed to meet the needs of pulmonologists, internists, nurse practitioners, and physician assistants involved in the treatment of patients with idiopathic pulmonary fibrosis.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the underlying mechanisms of lung injury and repair that contribute to the development of IPF
- Utilize the clinical criteria and diagnostic tools for identifying IPF, including focus on the importance of a multidisciplinary discussion
- Assess the clinical data for the current and emerging treatments for IPF, including the mechanism of action, efficacy, and limitations of therapy options
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this educational enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this educational enduring activity for a maximum of 0.5 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Mary Beth Scholand, MD | Dr. Scholand discloses that she served as a consultant for Boehringer Ingelheim, United Therapeutics, Avalyn Pharma, Bristol Myers Squibb, Trevi Therapeutics. She has conducted research for Boehringer Ingelheim, United Therapeutics, Calluna, Avalyn, Vicore Pharma, Glaxo Smith Kline, aTyr Pharma, Bristol Myers Squibb, Mediar Therapeutics. Dr. Scholand has also been a part of the Speakers Bureau for Boehringer Ingelheim, United Therapeutics, Insmed and DSM for Tvardi Therapeutics and Endeavor BioMedicines. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Anita Misra-Press, Medical Director for Med Learning Group, has nothing to disclose.
- Nicolas Applyrs Jr, DO, MS, MPH, has nothing to disclose.
- Sarah Milano RN, MSN, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, M.M., Accreditation & Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Elizabeth Griffin, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: August 10, 2026
EXPIRATION DATE: August 10, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
